- 全部删除
您的购物车当前为空
SKLB 1028 (Ruserontinib) 是口服活性的、新型的EGFR、FLT3和Abl 多激酶抑制剂。SKLB 1028 在FLT3驱动的AML 模型中显示出优异的活性,在含有Abl 突变体的CML 模型中显示了相当大的效力


为众多的药物研发团队赋能,
让新药发现更简单!
SKLB 1028 (Ruserontinib) 是口服活性的、新型的EGFR、FLT3和Abl 多激酶抑制剂。SKLB 1028 在FLT3驱动的AML 模型中显示出优异的活性,在含有Abl 突变体的CML 模型中显示了相当大的效力
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 497 | In stock | |
| 5 mg | ¥ 1,230 | In stock | |
| 10 mg | ¥ 1,960 | In stock | |
| 25 mg | ¥ 3,970 | In stock | |
| 50 mg | ¥ 5,660 | In stock | |
| 100 mg | ¥ 7,680 | In stock | |
| 200 mg | ¥ 9,870 | In stock | |
| 1 mL x 10 mM (in DMSO) | ¥ 1,210 | In stock |
SKLB 1028 相关产品
| 产品描述 | SKLB 1028 (Ruserontinib) is a new type of oral multikinase inhibitor of EGFR, FLT3, and Abl. SKLB 1028 shows excellent activity in FLT3-driven AML models and considerable potency in CML models containing Abl mutants. |
| 别名 | Ruserontinib |
| 分子量 | 443.55 |
| 分子式 | C24H29N9 |
| CAS No. | 1350544-93-2 |
| Smiles | C(C)(C)N1C=2C(N=C1NC=3C=CC=NC3)=CN=C(NC4=CC=C(C=C4)N5CCN(C)CC5)N2 |
| 密度 | 1.32 g/cm3 (Predicted) |
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| 溶解度信息 | DMSO: 50 mg/mL (112.73 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
评论内容